Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,458 JPY | -2.47% | +0.55% | +2.60% |
Sales 2024 * | 35.22B 225M | Sales 2025 * | 38.94B 248M | Capitalization | 134B 853M |
---|---|---|---|---|---|
Net income 2024 * | 951M 6.07M | Net income 2025 * | 3.47B 22.14M | EV / Sales 2024 * | 3.49 x |
Net cash position 2024 * | 10.81B 68.99M | Net cash position 2025 * | 12.21B 77.89M | EV / Sales 2025 * | 3.12 x |
P/E ratio 2024 * |
66.7
x | P/E ratio 2025 * |
26.4
x | Employees | 350 |
Yield 2024 * |
-
| Yield 2025 * |
0.05% | Free-Float | 88.87% |
Latest transcript on Nxera Pharma Co., Ltd.
1 day | -2.47% | ||
1 week | +0.55% | ||
Current month | -12.27% | ||
1 month | -9.67% | ||
3 months | +2.68% | ||
6 months | +8.81% | ||
Current year | +2.60% |
Managers | Title | Age | Since |
---|---|---|---|
Chris Cargill
CEO | Chief Executive Officer | 40 | 17-09-19 |
Shinichi Tamura
FOU | Founder | 74 | 90-06-21 |
Director of Finance/CFO | - | 22-03-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Shinichi Tamura
FOU | Founder | 74 | 90-06-21 |
Noriaki Nagai
BRD | Director/Board Member | 66 | 19-03-26 |
Rolf Soderstrom
BRD | Director/Board Member | 58 | 20-03-24 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
7.92% | 24 M€ | -14.52% | ||
1.17% | 16 M€ | -8.49% | ||
0.55% | 15 M€ | +7.34% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 1,458 | -2.47% | 3 093 200 |
24-04-25 | 1,495 | -0.86% | 731,300 |
24-04-24 | 1,508 | +1.89% | 708,600 |
24-04-23 | 1,480 | +0.89% | 584,900 |
24-04-22 | 1,467 | +1.17% | 602,200 |
Delayed Quote Japan Exchange, April 26, 2024 at 02:00 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.60% | 860M | |
-4.66% | 87.53B | |
+2.63% | 40.42B | |
-21.76% | 29.48B | |
+56.21% | 25.43B | |
-14.78% | 15.59B | |
-18.49% | 11.49B | |
-15.61% | 11.1B | |
-44.02% | 11.3B | |
+4.42% | 8.75B |
- Stock Market
- Equities
- 4565 Stock